美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

美国抗疫概念

1,357.02

-17.3577-1.26%

涨家数：4

跌家数：16

平家数：- -

市盈率：- -

高：1,368.58

开：1,368.58

低：1,344.11

收：1,374.50

数据加载中...

BUZZ-辉瑞公司季度利润超预期，维持 2025 年预期；股价上涨

Co-Diagnostics, Inc.盘中异动急速拉升5.07%报0.390美元

更正后的简报-FDA 称肝素钠注射液，5000 [Usp'u]/1 毫升将因商业决定而停产 - 网站

美股异动丨辉瑞涨超3% Q1经调整每股盈利远超预期扩大成本削减力度

辉瑞盘中异动早盘快速拉升3.01%

辉瑞(PFE.N)涨近3%。

Aethlon Medical, Inc.盘中异动早盘股价大涨5.04%

Equillium, Inc.盘中异动股价大跌6.12%

新冠疫苗研发波折：Vaxart 获转机，行业仍陷困境

生物制品圈

Ibio, Inc.盘中异动快速上涨6.19%报1.12美元

Corvus Pharmaceuticals, Inc.盘中异动早盘股价大涨5.43%报3.69美元

美国食品和药物管理局局长称解雇不会妨碍该局的药物审查目标日期

BUZZ-辉瑞公司季度利润增长，维持 2025 年业绩预期

辉瑞依靠削减成本抵消收入下降的影响

辉瑞季度销售额不及预期，COVID 治疗收入下降

阿斯利康一季报：中国区收入18亿美元，ADC药物驱动新增长

21世纪经济报道

阿斯利康盘前挫2.65% 将终止针对其前列腺癌治疗药物三期临床试验

美股异动丨阿斯利康盘前跌超3% 首季收入逊预期或因未支付进口税面临中国罚款

阿斯利康(AZN.O)CEO：美国关税对阿斯利康的影响将是短暂的。

阿斯利康 Q1：中国区收入 18 亿美元，Enhertu 大卖 10.86 亿美元

Insight数据库

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券 | 轻松买卖美股港股A股/美债/ETF/Crypto/期权期货","description":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","keywords":"老虎证券,老虎证券开户,老虎证券香港,老虎证券登录,老虎证券官网,香港证券开户,证券公司开户,股票开户,香港证券公司,香港证券,证券公司,股票投资,投资app,投资平台,股票买卖,股票交易平台,股票app,证券app,新手投资","social":{"ogDescription":"老虎证券提供多项优惠： 港股&Crypto 0佣0平台费、A股通一年免佣、美股期权0佣、IPO打新0融资利息0手续费。 美股1美元起投，免费实时行情与多种工具，立即开户享更多优惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK4568/news?page=3"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"美国抗疫概念","latestPrice":1357.1451,"timestamp":1746127281762,"preClose":1374.5028,"halted":0,"volume":67666420,"delay":0,"changeRate":-0.012628,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":-17.357666,"latestTime":"05-01 15:21:21 EDT","open":1368.5793,"high":1368.5793,"low":1344.1106,"amount":2905224328.244119,"amplitude":0.017802,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1746129600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.657153,"peRate":21.867348,"turnoverRate":0.004363,"increases":4,"decrements":16,"flats":0,"marketCap":1120687764778,"floatMarketCap":1101099937680},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1368.5793,"amplitude":0.017802,"preClose":1374.5028,"low":1344.1106,"pbRate":"3.657153","latestPrice":1357.0232,"volume":67661357,"delay":0,"open":1368.5793,"prevYearClose":1274.8187,"prevWeekClose":1341.1263,"prevMonthClose":1374.5028,"prevQuarterClose":1427.887,"fiveDayClose":1349.2345,"twentyDayClose":1385.3414,"sixtyDayClose":1349.0913,"secType":"PLATE","market":"US","turnoverRate":0.004362,"peRate":21.867348,"marketCap":1120647164010,"floatMarketCap":1101059828048,"timestamp":1746127278860,"nameCN":"美国抗疫概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":4,"down":16,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531766955","title":"BUZZ-辉瑞公司季度利润超预期，维持 2025 年预期；股价上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2531766955","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531766955?lang=zh_cn&edition=fundamental","pubTime":"2025-04-30 00:41","pubTimestamp":1745944911,"startTime":"0","endTime":"0","summary":"** 由于 Paxlovid COVID-19 疗法销售额下降，PFE 第一季度营收不及预期，但该公司仍 坚持610 亿至 640 亿美元的财年营收预期。** 包括本交易日的走势在内，PFE 在今年已累计下跌约10(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL4T3R723X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","LU0122379950.USD","LU1066053197.SGD","IE00BBT3K403.USD","SG9999011175.SGD","LU0456855351.SGD","LU1023059063.AUD","LU0868494617.USD","BK4568","LU1057294990.SGD","SG9999013999.USD","BK4533","PFE","BK4581","IE00B19Z3B42.SGD","SG9999001176.SGD","LU0170899867.USD","BK4585","LU0234572021.USD","LU0321505868.SGD","LU1894683348.USD","IE0002270589.USD","BK4007","LU1066051498.USD","LU1894683264.USD","BK4599","SG9999003800.SGD","LU0225771236.USD","LU1883839398.USD","LU0321505439.SGD","IE000M9KFDE8.USD","BK4534","LU0225284248.USD","BK4588","IE00BLSP4452.SGD","SGXZ57979304.SGD","BK4592","LU0306806265.USD","IE00B19Z3581.USD","SG9999002232.USD","LU0306807586.USD","IE00BLSP4239.USD","BK4550","SG9999001176.USD","LU0058720904.USD","LU0985481810.HKD","SG9999002224.SGD"],"gpt_icon":1},{"id":"2531577377","title":"Co-Diagnostics, Inc.盘中异动 急速拉升5.07%报0.390美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531577377","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531577377?lang=zh_cn&edition=fundamental","pubTime":"2025-04-29 23:27","pubTimestamp":1745940471,"startTime":"0","endTime":"0","summary":"北京时间2025年04月29日23时27分，Co-Diagnostics, Inc.股票出现波动，股价快速上涨5.07%。Co-Diagnostics, Inc.股票所在的医疗器械行业中，整体涨幅为0.10%。Co-Diagnostics, Inc.公司简介：Co-Diagnostics Inc是一家分子诊断公司。该公司还利用其专有技术为其 Co-Dx PCR 平台设计特定测试，并定位用于传染病以外应用的遗传标记。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429232751974a5c7c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429232751974a5c7c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4082","CODX","BK4568"],"gpt_icon":0},{"id":"2531752002","title":"更正后的简报-FDA 称肝素钠注射液，5000 [Usp'u]/1 毫升将因商业决定而停产 - 网站","url":"https://stock-news.laohu8.com/highlight/detail?id=2531752002","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531752002?lang=zh_cn&edition=fundamental","pubTime":"2025-04-29 23:24","pubTimestamp":1745940292,"startTime":"0","endTime":"0","summary":"更正后的简报-FDA 称肝素钠注射液，5000 [Usp'u]/1 毫升将因商业决定而停产 - 网站来源更正为美国食品及药物管理局，而非辉瑞公司路透4月29日 - 美国食品和药物管理局：FDA：肝素钠，注射剂，5000[USP'U]/1 毫升，因商业决定将停产 - 网站(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL4S3R71YJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B19Z3B42.SGD","LU0122379950.USD","BK4585","BK4533","IE00BLSP4452.SGD","LU0234572021.USD","SG9999001176.USD","LU0170899867.USD","BK4550","LU0985481810.HKD","LU1883839398.USD","IE000M9KFDE8.USD","LU0456855351.SGD","SG9999011175.SGD","LU1066053197.SGD","IE00B19Z3581.USD","LU1066051498.USD","LU0306806265.USD","SG9999002232.USD","LU1023059063.AUD","LU1057294990.SGD","BK4534","BK4592","LU0225771236.USD","SGXZ57979304.SGD","SG9999003800.SGD","IE00BLSP4239.USD","BK4599","BK4581","IE00BBT3K403.USD","LU0225284248.USD","SG9999001176.SGD","LU0058720904.USD","LU1894683348.USD","LU0306807586.USD","LU0321505868.SGD","BK4007","LU0321505439.SGD","SG9999013999.USD","SG9999002224.SGD","BK4568","IE0002270589.USD","LU0868494617.USD","LU0289739699.SGD","LU1894683264.USD"],"gpt_icon":0},{"id":"2531757594","title":"美股异动丨辉瑞涨超3% Q1经调整每股盈利远超预期 扩大成本削减力度","url":"https://stock-news.laohu8.com/highlight/detail?id=2531757594","media":"格隆汇APP","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531757594?lang=zh_cn&edition=fundamental","pubTime":"2025-04-29 23:11","pubTimestamp":1745939460,"startTime":"0","endTime":"0","summary":"格隆汇4月29日｜辉瑞(PFE.US)涨超3%，报23.755美元。消息面上，辉瑞周二公布，在加大成本削减力度下，首季净利润同比跌约5%至29.7亿美元，经调整每股盈利92美仙，远高于市场预期的66美仙；营收同比跌8%至137.2亿美元，反映其抗病毒药物Paxlovid的收入减少。公司预计，通过两项成本削减措施，到2027年底将节省约77亿美元。公司维持对2025年全年财报的预期，预计销售额为610亿至640亿美元，惟补充该指引目前不包括与未来关税和贸易政策变化相关的任何潜在影响。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2025-04-29/doc-ineuwcvn0721829.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4550","LU0321505868.SGD","LU0225284248.USD","LU1023059063.AUD","IE000M9KFDE8.USD","LU1066053197.SGD","IE00BLSP4452.SGD","LU0225771236.USD","BK4534","SG9999003800.SGD","IE0002270589.USD","SG9999013999.USD","LU0122379950.USD","BK4581","BK4585","IE00BLSP4239.USD","LU0306807586.USD","LU1894683264.USD","LU0234572021.USD","SG9999002232.USD","LU0058720904.USD","LU0289739699.SGD","SG9999011175.SGD","IE00B19Z3B42.SGD","LU1894683348.USD","BK4599","BK4588","BK4007","IE00BBT3K403.USD","BK4568","SGXZ57979304.SGD","PFE","SG9999001176.USD","IE00B19Z3581.USD","BK4592","LU0321505439.SGD","LU1066051498.USD","LU0306806265.USD","SG9999002224.SGD","LU0868494617.USD","LU0985481810.HKD","LU1883839398.USD","SG9999001176.SGD","LU0170899867.USD","LU1057294990.SGD","LU0456855351.SGD","BK4533"],"gpt_icon":0},{"id":"2531545567","title":"辉瑞盘中异动 早盘快速拉升3.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531545567","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531545567?lang=zh_cn&edition=fundamental","pubTime":"2025-04-29 22:50","pubTimestamp":1745938226,"startTime":"0","endTime":"0","summary":"北京时间2025年04月29日22时50分，辉瑞股票出现异动，股价急速拉升3.01%。截至发稿，该股报23.74美元/股，成交量3271.13万股，换手率0.58%，振幅5.53%。辉瑞股票所在的制药行业中，整体涨幅为1.01%。辉瑞公司简介：辉瑞是全球最大的制药公司之一，年销售额接近500亿美元。辉瑞在全球销售这些产品，国际销售额占其总销售额的近50%。与其他受贸易政策变化影响的公司不同，辉瑞并未调整其业绩预期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429225026aa2c7e45&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429225026aa2c7e45&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","LU0456855351.SGD","LU0985481810.HKD","BK4007","SG9999013999.USD","IE00BLSP4239.USD","BK4581","LU0234572021.USD","LU1894683348.USD","BK4592","SG9999011175.SGD","IE00BBT3K403.USD","SGXZ57979304.SGD","LU0306806265.USD","BK4534","LU1894683264.USD","LU0170899867.USD","IE00B19Z3581.USD","LU0225284248.USD","LU0321505439.SGD","SG9999002224.SGD","LU0321505868.SGD","LU1066051498.USD","LU1023059063.AUD","BK4533","SG9999001176.USD","IE00B19Z3B42.SGD","SG9999003800.SGD","LU0289739699.SGD","LU0868494617.USD","PFE","LU0058720904.USD","IE0002270589.USD","LU0306807586.USD","BK4588","LU0225771236.USD","BK4568","IE000M9KFDE8.USD","SG9999001176.SGD","BK4550","BK4599","LU1066053197.SGD","SG9999002232.USD","LU0122379950.USD","LU1883839398.USD","LU1057294990.SGD","IE00BLSP4452.SGD"],"gpt_icon":1},{"id":"2531751539","title":"辉瑞(PFE.N)涨近3%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2531751539","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531751539?lang=zh_cn&edition=fundamental","pubTime":"2025-04-29 22:48","pubTimestamp":1745938133,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4568","BK4588","SG9999013999.USD","SG9999002224.SGD","LU0321505439.SGD","SG9999001176.USD","LU0306806265.USD","IE00BBT3K403.USD","BK4599","LU1066051498.USD","LU1066053197.SGD","PFE","SG9999001176.SGD","IE00BLSP4452.SGD","BK4534","IE00B19Z3581.USD","SG9999002232.USD","BK4007","LU0868494617.USD","LU0170899867.USD","LU0225284248.USD","LU0234572021.USD","IE0002270589.USD","LU0456855351.SGD","LU1883839398.USD","IE00B19Z3B42.SGD","BK4533","SG9999003800.SGD","LU1894683348.USD","LU0122379950.USD","LU0058720904.USD","LU1894683264.USD","SG9999011175.SGD","LU1057294990.SGD","IE000M9KFDE8.USD","IE00BLSP4239.USD","BK4550","LU0306807586.USD","LU0289739699.SGD","LU0985481810.HKD","BK4581","LU0321505868.SGD","BK4592","BK4585","LU1023059063.AUD","SGXZ57979304.SGD","LU0225771236.USD"],"gpt_icon":0},{"id":"2531755299","title":"Aethlon Medical, Inc.盘中异动 早盘股价大涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531755299","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531755299?lang=zh_cn&edition=fundamental","pubTime":"2025-04-29 22:07","pubTimestamp":1745935664,"startTime":"0","endTime":"0","summary":"北京时间2025年04月29日22时07分，Aethlon Medical, Inc.股票出现异动，股价急速拉升5.04%。截至发稿，该股报0.417美元/股，成交量2.6382万股，换手率0.16%，振幅3.78%。Aethlon Medical, Inc.股票所在的医疗器械行业中，整体涨幅为0.45%。其相关个股中，Inspiremd Inc.、Autonomix Medical, Inc.、飞天兆业涨幅较大，Tivic Health Systems, Inc.、Invo Fertility, Inc.、Autonomix Medical, Inc.较为活跃，换手率分别为29.14%、20.66%、12.27%，振幅较大的相关个股有Tivic Health Systems, Inc.、Autonomix Medical, Inc.、Dih Holding Us, Inc.，振幅分别为18.01%、17.95%、15.10%。Aethlon Medical, Inc.公司简介：Aethlon Medical Inc 是一家医疗技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429220744a46c4925&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429220744a46c4925&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","TIVC","BK4583","AEMD","BK4082"],"gpt_icon":0},{"id":"2531275347","title":"Equillium, Inc.盘中异动 股价大跌6.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2531275347","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531275347?lang=zh_cn&edition=fundamental","pubTime":"2025-04-29 21:57","pubTimestamp":1745935059,"startTime":"0","endTime":"0","summary":"北京时间2025年04月29日21时57分，Equillium, Inc.股票出现异动，股价快速下跌6.12%。Equillium, Inc.股票所在的生物技术行业中，整体跌幅为1.40%。Equillium, Inc.公司简介：Equillium Inc是一家临床阶段的生物技术公司，致力于开发新的治疗方法，以治疗严重的自身免疫性和炎症性疾病，或免疫炎症性疾病，具有高度未满足的医疗需求。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429215741974a4142&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429215741974a4142&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","EQ","BK4568"],"gpt_icon":0},{"id":"2531134867","title":"新冠疫苗研发波折：Vaxart 获转机，行业仍陷困境","url":"https://stock-news.laohu8.com/highlight/detail?id=2531134867","media":"生物制品圈","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531134867?lang=zh_cn&edition=fundamental","pubTime":"2025-04-29 21:56","pubTimestamp":1745935014,"startTime":"0","endTime":"0","summary":"近日，疫苗研发领域动态频出，Vaxart 公司迎来好消息，其新冠疫苗研究的暂停令被解除，研发进程得以重启。此前，HHS 在 2 月冻结了 Vaxart 的试验，这一举措使得该公司与政府签订的价值数十亿美元的口服新冠疫苗研发合同陷入僵局。其他公司受阻，研发之路艰难尽管 Vaxart 迎来转机，但其他新冠疫苗研发企业却仍在困境中挣扎。Vaxart 公司新冠疫苗研究的恢复为其带来了希望，但新冠疫苗研发行业整体仍面临监管、舆论等多方面的压力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430052357a46cac01&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430052357a46cac01&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","BK4139","BK4009","VXRT","HHS"],"gpt_icon":0},{"id":"2531312730","title":"Ibio, Inc.盘中异动 快速上涨6.19%报1.12美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531312730","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531312730?lang=zh_cn&edition=fundamental","pubTime":"2025-04-29 21:33","pubTimestamp":1745933617,"startTime":"0","endTime":"0","summary":"北京时间2025年04月29日21时33分，Ibio, Inc.股票出现异动，股价急速上涨6.19%。截至发稿，该股报1.12美元/股，成交量12.66万股，换手率1.26%，振幅3.81%。Ibio, Inc.股票所在的生物技术行业中，整体跌幅为1.92%。Ibio, Inc.公司简介：iBio公司是一家临床前阶段生物技术公司，利用人工智能的力量开发精准抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429213337aa2c7e03&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429213337aa2c7e03&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IBIO","BK4568"],"gpt_icon":0},{"id":"2531410753","title":"Corvus Pharmaceuticals, Inc.盘中异动 早盘股价大涨5.43%报3.69美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531410753","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531410753?lang=zh_cn&edition=fundamental","pubTime":"2025-04-29 21:32","pubTimestamp":1745933547,"startTime":"0","endTime":"0","summary":"北京时间2025年04月29日21时32分，Corvus Pharmaceuticals, Inc.股票出现异动，股价急速拉升5.43%。Corvus Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为1.55%。其相关个股中，Cyclacel Pharmaceuticals, Inc.、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Tevogen Bio Holdings Inc C/Wts 14/02/2029 涨幅较大，Zyversa Therapeutics, Inc.、Onconetix, Inc.、Galmed Pharmaceuticals Ltd.较为活跃，换手率分别为132.52%、39.26%、11.58%，振幅较大的相关个股有Cyclacel Pharmaceuticals, Inc.、Ernexa Therapeutics Inc.、Promis Neurosciences Inc.，振幅分别为12.12%、12.10%、9.62%。Corvus Pharmaceuticals, Inc.公司简介：Corvus Pharmaceuticals Inc 是一家临床阶段的生物制药公司，致力于开发针对免疫系统关键细胞元素的药物和抗体。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429213228aa2c7e00&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429213228aa2c7e00&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4568","CRVS"],"gpt_icon":0},{"id":"2531773684","title":"美国食品和药物管理局局长称解雇不会妨碍该局的药物审查目标日期","url":"https://stock-news.laohu8.com/highlight/detail?id=2531773684","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531773684?lang=zh_cn&edition=fundamental","pubTime":"2025-04-29 20:42","pubTimestamp":1745930559,"startTime":"0","endTime":"0","summary":"美国食品和药物管理局局长表示，尽管特朗普政府大规模解雇了该机构的人员，但美国食品和药物管理局仍将实现完成新药审查的目标。路透 4 月初报道称，该机构大规模解雇 了 对新药审评 至关重要的   员工，包括所有负责管理新产品申请等记录的 员工。马卡里还表示，他可以在该机构独立做出决定。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL4S3R71CH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4547","BK4588","BK4139","BK4568","BK4585"],"gpt_icon":1},{"id":"2531641786","title":"BUZZ-辉瑞公司季度利润增长，维持 2025 年业绩预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2531641786","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531641786?lang=zh_cn&edition=fundamental","pubTime":"2025-04-29 19:02","pubTimestamp":1745924560,"startTime":"0","endTime":"0","summary":"** 虽然第一季度营收不及预期，但仍坚持610-640亿美元的财年营收预期 ** 同时，维持 2.80 美元至 3.00 美元的财年每股收益预期。** 截至上次收盘，PFE 年累计下跌约 13 (为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL4T3R7114:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002232.USD","LU0321505868.SGD","LU1023059063.AUD","PFE","BK4585","BK4534","LU1057294990.SGD","SG9999002224.SGD","BK4007","LU0058720904.USD","BK4581","LU0868494617.USD","LU0306807586.USD","SG9999011175.SGD","BK4568","LU1066051498.USD","LU0456855351.SGD","BK4533","SG9999003800.SGD","LU0321505439.SGD","BK4599","LU0122379950.USD","LU1894683348.USD","LU0225771236.USD","BK4550","LU0306806265.USD","BK4592","SG9999013999.USD","IE00BBT3K403.USD","SG9999001176.SGD","LU0289739699.SGD","LU1894683264.USD","LU0170899867.USD","LU1066053197.SGD","LU0985481810.HKD","SG9999001176.USD","IE00B19Z3B42.SGD","SGXZ57979304.SGD","IE00BLSP4239.USD","IE0002270589.USD","LU1883839398.USD","IE000M9KFDE8.USD","IE00B19Z3581.USD","LU0225284248.USD","LU0234572021.USD","BK4588","IE00BLSP4452.SGD"],"gpt_icon":0},{"id":"2531785467","title":"辉瑞依靠削减成本抵消收入下降的影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2531785467","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531785467?lang=zh_cn&edition=fundamental","pubTime":"2025-04-29 19:00","pubTimestamp":1745924425,"startTime":"0","endTime":"0","summary":"更新版 6-辉瑞依靠削减成本抵消收入下降的影响辉瑞公布喜忧参半的第一季度业绩，维持全年预期 COVID 疫苗销售好于预期，而抗病毒治疗销售下降预计到 2027 年底可节省 77 亿美元成本 第 8-9 段增加了首席执行官访谈中关于关税的评论Bhanvi Satija/Michael Erman. 路透4月29日 - 辉瑞PFE.N周二表示，公司将通过削减生产和研究业务的成本再节约17亿美元，尽管由于其COVID-19治疗药物Paxlovid的销售下降导致第一季度收入减少，但辉瑞仍强调了其运营效率。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL4T3R7108:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","BK4588","LU0122379950.USD","LU1066053197.SGD","LU1066051498.USD","IE00BLSP4452.SGD","BK4568","LU1894683264.USD","LU0985481810.HKD","SGXZ57979304.SGD","BK4581","IE00BBT3K403.USD","LU1057294990.SGD","LU0225284248.USD","SG9999001176.USD","IE0002270589.USD","LU1883839398.USD","LU0225771236.USD","LU0868494617.USD","SG9999013999.USD","SG9999002224.SGD","LU0170899867.USD","BK4585","LU0234572021.USD","BK4533","LU0321505868.SGD","BK4550","SG9999011175.SGD","LU0306807586.USD","IE00B19Z3B42.SGD","IE00BLSP4239.USD","PFE","LU1023059063.AUD","LU0058720904.USD","BK4592","LU0321505439.SGD","SG9999001176.SGD","IE000M9KFDE8.USD","LU0306806265.USD","LU0289739699.SGD","BK4007","BK4599","LU1894683348.USD","SG9999003800.SGD","SG9999002232.USD","LU0456855351.SGD","IE00B19Z3581.USD"],"gpt_icon":1},{"id":"2531378394","title":"辉瑞季度销售额不及预期，COVID 治疗收入下降","url":"https://stock-news.laohu8.com/highlight/detail?id=2531378394","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531378394?lang=zh_cn&edition=fundamental","pubTime":"2025-04-29 18:49","pubTimestamp":1745923795,"startTime":"0","endTime":"0","summary":"辉瑞季度销售额不及预期，COVID 治疗收入下降路透4月29日 - 美国制药商辉瑞PFE.N周二公布的第一季度收入低于华尔街预期，受其COVID抗病毒治疗药物Paxlovid销售下滑的影响。 LSEG的数据显示，该公司第一季度总营收为137.0亿美元，而分析师预期为139.1亿美元。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250429:nL4S3R70Z5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4592","IE00BBT3K403.USD","LU0170899867.USD","LU0058720904.USD","BK4588","LU0868494617.USD","LU0306806265.USD","BK4581","BK4568","LU1894683264.USD","IE00B19Z3B42.SGD","LU0122379950.USD","BK4599","LU0321505868.SGD","IE00B19Z3581.USD","LU0289739699.SGD","LU0225284248.USD","IE00BLSP4452.SGD","SG9999002224.SGD","BK4533","LU0306807586.USD","BK4585","IE00BLSP4239.USD","LU1883839398.USD","LU1057294990.SGD","LU0234572021.USD","LU0985481810.HKD","LU1066053197.SGD","LU1023059063.AUD","SG9999003800.SGD","SG9999011175.SGD","IE000M9KFDE8.USD","IE0002270589.USD","SG9999013999.USD","BK4534","SG9999002232.USD","LU0321505439.SGD","BK4007","LU0225771236.USD","PFE","SG9999001176.USD","LU0456855351.SGD","SG9999001176.SGD","BK4550","SGXZ57979304.SGD","LU1894683348.USD","LU1066051498.USD"],"gpt_icon":0},{"id":"2531022292","title":"阿斯利康一季报：中国区收入18亿美元，ADC药物驱动新增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2531022292","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531022292?lang=zh_cn&edition=fundamental","pubTime":"2025-04-29 17:56","pubTimestamp":1745920574,"startTime":"0","endTime":"0","summary":"根据财报，今年一季度阿斯利康在美国收入 56.46 亿美元，同比增长10%，占总营收的 42%；中国区收入 18.05 亿美元，同比增长5%，占总营收的 13%。而ADC 药物德曲妥珠单抗增长势头强劲，今年第一季度的销售额为10.86 亿美元。阿斯利康的财报印证了其在“专利悬崖”前的未雨绸缪：通过ADC药物打开新增量，以多元化管线平衡风险，并借力中国市场实现全球化纵深。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504291758349749f61d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504291758349749f61d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","ADC","BK4231","LU1829250122.USD","AZN","LU2236285917.USD","BK4585","LU2462157665.USD","BK4588","LU0320765992.SGD","LU2456880835.USD","LU0889565916.HKD","BK4080","LU0109394709.USD","LU2417539215.USD","BK4007"],"gpt_icon":0},{"id":"2531270717","title":"阿斯利康盘前挫2.65% 将终止针对其前列腺癌治疗药物三期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2531270717","media":"金吾资讯","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531270717?lang=zh_cn&edition=fundamental","pubTime":"2025-04-29 17:00","pubTimestamp":1745917203,"startTime":"0","endTime":"0","summary":"金吾财讯 | 阿斯利康(AZN)盘前股价下挫，暂跌2.65%，报68.08美元。消息面上，公司将终止针对其前列腺癌治疗药物Truqap的CAPITello-280三期临床试验，原因是该试验不太可能达到双重主要终点。公司周二称，这一决定是在审查了独立数据监测委员会建议的中期分析数据后作出的。该公司表示，与使用多西他赛和雄激素剥夺疗法（ADT）加安慰剂的对照组相比，Truqap联合多西他赛和ADT的治疗方案，在转移性去势抵抗性前列腺癌患者中，可能无法达到影像学无进展生存期和总生存期的主要终点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504291701509749e2b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202504291701509749e2b7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1829250122.USD","LU2417539215.USD","BK4585","LU0889565916.HKD","BK4568","BK4007","LU0320765992.SGD","LU2456880835.USD","AZN","BK4588","LU2236285917.USD","LU0109394709.USD","LU2462157665.USD"],"gpt_icon":0},{"id":"2531475201","title":"美股异动丨阿斯利康盘前跌超3% 首季收入逊预期 或因未支付进口税面临中国罚款","url":"https://stock-news.laohu8.com/highlight/detail?id=2531475201","media":"格隆汇APP","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531475201?lang=zh_cn&edition=fundamental","pubTime":"2025-04-29 16:51","pubTimestamp":1745916660,"startTime":"0","endTime":"0","summary":"阿斯利康(AZN.US)盘前跌超3%，报67.81美元。消息面上，阿斯利康第一季度总营收135.9亿美元，同比增长10%，低于市场预期的138亿美元；核心每股收益2.49美元，同比增长21%。另外，由于涉嫌在中国未缴纳进口税，该公司已收到深圳市有关部门的意见，认为疑似未支付的金额约为160万美元，如果被认定负有责任，可能会被处以一至五倍的罚款。(格隆汇)\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2025-04-29/doc-ineuvnxv5672354.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4568","LU0109394709.USD","LU0889565916.HKD","LU2456880835.USD","BK4588","LU0320765992.SGD","LU1829250122.USD","BK4007","BK4585","LU2417539215.USD","LU2462157665.USD","AZN","LU2236285917.USD"],"gpt_icon":0},{"id":"2531211672","title":"阿斯利康(AZN.O)CEO：美国关税对阿斯利康的影响将是短暂的。","url":"https://stock-news.laohu8.com/highlight/detail?id=2531211672","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531211672?lang=zh_cn&edition=fundamental","pubTime":"2025-04-29 14:51","pubTimestamp":1745909467,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK4585","LU0889565916.HKD","BK4568","AZN","LU2417539215.USD","LU2456880835.USD","LU2462157665.USD","LU2236285917.USD","LU0320765992.SGD","BK4007","LU1829250122.USD","BK4588","LU0109394709.USD"],"gpt_icon":0},{"id":"2531224997","title":"阿斯利康 Q1：中国区收入 18 亿美元，Enhertu 大卖 10.86 亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2531224997","media":"Insight数据库","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531224997?lang=zh_cn&edition=fundamental","pubTime":"2025-04-29 14:25","pubTimestamp":1745907932,"startTime":"0","endTime":"0","summary":"4 月 29 日，阿斯利康发布 2025 年一季度财报，营收 135.88 亿美元，同比增长 10%，其中产品收入销售 128.75 亿美元（+9%）。来源：阿斯利康 2025 Q1 财报，下同从地区来看，美国收入 56.46 亿美元，占总营收的 42%；中国是阿斯利康继美国、欧洲后的第三大市场，今年 Q1 收入 18.05 亿美元（+5%），占总营收的 13%。ADC 方面，德曲妥珠单抗是第一三共和阿斯利康携手打造的第一款 ADC，自 2019 年 12 月上市以来，短短 5 年时间，24 年销售额便已突破 34 亿美元，25 年有望超过 40 亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429150336a6ccca72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250429150336a6ccca72&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320765992.SGD","BK4007","LU2462157665.USD","LU1829250122.USD","LU2236285917.USD","LU2456880835.USD","BK4568","BK4585","BK4588","LU0889565916.HKD","LU2417539215.USD","AZN","LU0109394709.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":188,"code":"91000000","status":"200"}]}}